Option chain shows key data for BioVie's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioVie.

BioVie (NASDAQ:BIVI) Stock, Option Chain

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADXN

ATNI

BIVI

BOOM

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Spirit_Airlines-Wikimedia Commons

AGFY

APVO

EFSH

JDZG

LGMK

MTEM

NKGN

PHIO

SAVE

SHLS

TNON

VSEE

VSME

VTAK

XPON

ZPTA

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

Crude-oil-4-logo

Earnings

Equities

Eurozone

Commodities

LASE

Merrill Lynch & Strategic Return Notes for Select 10 Index

SEEL

Crude Oil Gains Over 1%; BioVie Shares Plunge

BioVie Inc

BIVICTRIX THERAPEUTICS PL by BIVICTRIX THERAPEUTICS PLC

BiVictriX Therapeutics PLC

Press Releases

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

Financing

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Health Care

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering

BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

Legal

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Abpro Hldgs

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allakos

BioAtla

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Celularity

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Curis

CervoMed

CEL-SCI

Cyclo Therapeutics

Equillium

HCW Biologics

HOOKIPA Pharma

IN8bio

Longeveron

Lisata Therapeutics

NKGen Biotech

Nanoviricides

NextCure

Palatin Techs

Q32 Bio

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

Unity Biotechnology

ThinkEquity

Oppenheimer

Cantor Fitzgerald

EF Hutton

BIOVIE INC by BioVie Inc.

Comments

BioVie

BioVie (BIVI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga